CFO and Chief Business Officer at FogPharma
As CFO and CBO, Mr. Gibney oversees and drives the business development and finance functions of the company. Mr. Gibney brings over 25 years of investment banking experience dedicated to advising biotech companies in the U.S. and Europe on substantial corporate M&A, partnering transactions, as well as executing financing transactions. Following his career in investment banking, Tony transitioned to the biotech industry to burnish his corporate strategy, business development skills and gain operational expertise, and to become directly involved in advancing compounds to treat diseases of high unmet need. Most recently, Mr. Gibney served as the Executive Vice President and Chief Business Officer of Achillion Pharmaceuticals, Inc., where he led corporate and portfolio strategy, business development and corporate communications. He collaborated with the CFO to manage relationships with the sell-side equity research analysts and develop long-range forecasts, valuation models and transaction-based scenario analyses, and led the process that concluded with the successful sale of Achillion to Alexion in 2020. Before Achillion, Mr. Gibney was a Managing Director and Co-Head of Biotechnology Investment Banking Team at Leerink Partners LLC. Mr. Gibney also previously worked in the Healthcare Group at Merrill Lynch, Inc., where he led the East Coast biotech effort as a Managing Director. Mr. Gibney began his professional career as an analyst in the Healthcare Investment Banking Group at Lehman Brothers Inc. He earned a B.A. in Economics and a B.A. in History from Yale University.